Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.07 +2.43%
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.20, $0.06 better than the analyst estimate of $0.14. Revenue for the quarter came in at $250.4 million versus the consensus estimate of $248.6 million.
GUIDANCE:
Acadia Pharma sees FY2024 revenue of $940-960 million, versus the consensus of $952.5 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Uber Inc. (UBER) PT Lowered to $90 at BTIG
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
